Wordt geladen...
Response to post-axitinib treatment in patients with metastatic renal cell carcinoma
BACKGROUND: Axitinib is a potent inhibitor of the vascular endothelial growth factor (VEGF) receptor family with clinical activity in patients with metastatic renal cell carcinoma (mRCC). Given this biochemical potency, the clinical activity of subsequent treatment with targeted therapies in patient...
Bewaard in:
| Gepubliceerd in: | BMC Cancer |
|---|---|
| Hoofdauteurs: | , , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
BioMed Central
2016
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4810513/ https://ncbi.nlm.nih.gov/pubmed/27026229 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2282-5 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|